* This work was supported in part by the Institute for the Study of
Aging and by the Israel Science Foundation, U.S.-Israel Binational
Science Foundation, Institute for the Study of Aging, and Allon Therapeutics, Inc. The costs of publication of this article were defrayed in
part by the payment of page charges. This article must therefore be
hereby marked “advertisement” in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§ This work is submitted in partial fulfillment of the requirements for
a Ph.D. at Tel Aviv University.
Holds the Lily and Avraham Gildor Chair for the Investigation of
Growth Factors. To whom correspondence should be addressed. Tel.:
972-3-6407240; Fax: 972-3-6408541; E-mail: igozes@post.tau.ac.il.
1 The abbreviations and trivial terms used are: NAP, octapeptide
containing the amino acid sequence of NAPVSIPQ; ADNP, activitydependent neuroprotective protein; VIP, vasoactive intestinal peptide; PIPES, 1,4-piperazinediethanesulfonic acid; MTS,
3-(4,5-dimethylthiazol-2-y1–5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium.
